References
- Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med (1999);131:207-19
- Altekruse S, Kosary CL, Krapcho M et al. SEER Cancer Statistics Review. 2011. Available at: http://seer.cancer.gov/csr/1975_2007/ [Last accessed 25 January 2012]
- Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood (2010);116:3758-65
- ELN. Recommendations from the European LeukemiaNet for the Management of chronic myeloid leukemia (CML). Available at: http://www.leukemia-net.org/content/leukemias/cml/recommendations/ [Last accessed 25 January 2012]
- NCCN. NCCN Guidelines Version 2.2011 – Chronic Myelogenous Leukemia. NCCN Guidelines, 2011
- US Food and Drug Administration: Dasatinib. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021986s009s010lbl.pdf [Last accessed 9 May 2012]
- Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract (2009);15:34-44
- US Food and Drug Administration: Nilotinib. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022068s012lbl.pdf [Last accessed 9 May 2012]
- Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood (2009);113:5401-11
- Doti C, Stemmelin G, Shanley C, et al. Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study. Blood (ASH Annual Meeting Abstracts) (2007);110: Abstract 4553
- Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol (2010);28:2381-8
- Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood (2011);10:3733-6
- Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med (2010);362:2260-70
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med (2010);362:2251-9
- Yood MU, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin (2012);28:213-19
- Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin (2010);26:2861-9
- Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics (2007);25:481-96
- Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health (2007);10:3-12
- Santos FPS, Kantarjian H, Fava C, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol (2010);150:303-12